{"id":"W1534401608","doi":"10.1016/s1470-2045(15)70137-3","title":"Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":134,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Epirubicin; Docetaxel; Clinical endpoint; Bevacizumab; Breast cancer; Internal medicine; Cyclophosphamide; Chemotherapy; Oncology; Fluorouracil; Neoadjuvant therapy; Mucositis; Phases of clinical research; Clinical trial; Surgery; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002241924,0.00143792,0.002168017,0.0004391651,0.0003664453,0.001116553,0.000795413,0.001748672,0.005145574],"category_scores_gemma":[0.00249336,0.0005344165,0.00156496,0.000403737,0.001377072,0.0009495613,0.0004087287,0.003051652,0.0009614739],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001446744,"about_ca_system_score_gemma":0.001365448,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009450543,"about_ca_topic_score_gemma":0.002878232,"domain_scores_codex":[0.9990566,0.0006055704,0.00004997215,0.0001338742,0.00006241081,0.00009154298],"domain_scores_gemma":[0.9984899,0.0004918621,0.0004001507,0.00008349268,0.00006222099,0.0004723434],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9787076,0.005731066,0.000467795,0.0003875846,0.0003397143,0.00003553121,0.00004783646,0.0003345011,0.002237964,0.00006287714,0.000454105,0.01119342],"study_design_scores_gemma":[0.8892051,0.1079684,0.001220612,0.00003324133,0.0001932423,0.00004764266,0.00001326782,0.000263905,0.0003694094,0.0001115755,0.000562956,0.00001066111],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865002,0.00565604,0.0005177726,0.0007951156,0.0004204026,0.003451053,0.000749016,0.00009473589,0.001815601],"genre_scores_gemma":[0.987905,0.002542143,0.001427027,0.000824194,0.0002998625,0.00403817,0.0009792943,0.00002183554,0.001962427],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005145574,"threshold_uncertainty_score":0.0172137,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04623737131073502,"score_gpt":0.3696223259041013,"score_spread":0.3233849545933662,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}